Environmental Health Sciences, Morrill I, N344, University of Massachusetts, Amherst, MA, 01003, United States.
7 West Melrose Avenue, Baltimore, MD, 21210, United States.
Pharmacol Res. 2021 Jan;163:105283. doi: 10.1016/j.phrs.2020.105283. Epub 2020 Nov 4.
In numerous experimental models, sulforaphane (SFN) is shown herein to induce hormetic dose responses that are not only common but display endpoints of biomedical and clinical relevance. These hormetic responses are mediated via the activation of nuclear factor erythroid- derived 2 (Nrf2) antioxidant response elements (AREs) and, as such, are characteristically biphasic, well integrated, concentration/dose dependent, and specific with regard to the targeted cell type and the temporal profile of response. In experimental disease models, the SFN-induced hormetic activation of Nrf2 was shown to effectively reduce the occurrence and severity of a wide range of human-related pathologies, including Parkinson's disease, Alzheimer's disease, stroke, age-related ocular damage, chemically induced brain damage, and renal nephropathy, amongst others, while also enhancing stem cell proliferation. Although SFN was broadly chemoprotective within an hormetic dose-response context, it also enhanced cell proliferation/cell viability at low concentrations in multiple tumor cell lines. Although the implications of the findings in tumor cells are largely uncertain at this time and warrant further consideration, the potential utility of SFN in cancer treatment has not been precluded. This assessment of SFN complements recent reports of similar hormesis-based chemoprotections by other widely used dietary supplements, such as curcumin, ginkgo biloba, ginseng, green tea, and resveratrol. Interestingly, the mechanistic profile of SFN is similar to that of numerous other hormetic agents, indicating that activation of the Nrf2/ARE pathway is probably a central, integrative, and underlying mechanism of hormesis itself. The Nrf2/ARE pathway provides an explanation for how large numbers of agents that both display hormetic dose responses and activate Nrf2 can function to limit age-related damage, the progression of numerous disease processes, and chemical- and radiation- induced toxicities. These findings extend the generality of the hormetic dose response to include SFN and many other chemical activators of Nrf2 that are cited in the biomedical literature and therefore have potentially important public health and clinical implications.
在许多实验模型中,本文显示萝卜硫素(SFN)可诱导激效剂量反应,这些反应不仅常见,而且具有生物医学和临床相关性的终点。这些激效反应是通过核因子红细胞衍生 2(Nrf2)抗氧化反应元件(AREs)的激活介导的,因此具有双相性、良好的整合性、浓度/剂量依赖性以及针对靶细胞类型和反应时间特征的特异性。在实验性疾病模型中,SFN 诱导的 Nrf2 激效激活被证明可有效降低一系列与人类相关的病理学的发生和严重程度,包括帕金森病、阿尔茨海默病、中风、年龄相关性眼部损伤、化学诱导的脑损伤和肾肾病等,同时还增强干细胞增殖。虽然 SFN 在激效剂量反应范围内具有广泛的化学保护作用,但它也在多种肿瘤细胞系中在低浓度下增强细胞增殖/细胞活力。虽然目前尚不完全清楚这些发现对肿瘤细胞的影响,需要进一步考虑,但 SFN 在癌症治疗中的潜在用途并未被排除。对 SFN 的评估补充了最近关于其他广泛使用的膳食补充剂(如姜黄素、银杏叶、人参、绿茶和白藜芦醇)的类似激效化学保护作用的报告。有趣的是,SFN 的机制特征与许多其他激效剂相似,这表明 Nrf2/ARE 途径的激活可能是激效本身的一个核心、综合和基础机制。Nrf2/ARE 途径为大量显示激效剂量反应并激活 Nrf2 的药物如何发挥作用以限制与年龄相关的损伤、许多疾病过程的进展以及化学和辐射诱导的毒性提供了解释。这些发现将激效剂量反应的普遍性扩展到包括 SFN 和许多其他在生物医学文献中引用的 Nrf2 化学激活剂,因此具有潜在的重要公共卫生和临床意义。